The objective of this review is to outline current major cancer targets for nanoparticle
systems and give insight into the direction of the field. The major targeting strategies that …

Cisplatin is used to treat a variety of tumors, but dose limiting toxicities or intrinsic and
acquired resistance limit its application in many types of cancer including prostate. We report …

Polymeric nanoparticles represent a form of targeted therapy due to their ability to passively
accumulate within the tumor interstitium via the enhanced permeability and retention (EPR) …

Prostate-specific membrane antigen is a type II transmembrane glycoprotein, expressed in
benign and neoplastic prostatic tissue as well as endothelial cells of neovasculature from a …

BACKROUND Prostate‐specific membrane antigen (PSMA) remains an attractive target for
imaging and therapeutic applications for prostate cancer. Recent efforts have been made to …

Increased expression of PSMA, a differentiation antigen with folate hydrolase activity, is an
independent marker of prostate cancer progression. Mice expressing moderate levels of …

Background Analysis of microarray data has been used for the inference of gene-gene
interactions. If, however, the aim is the discovery of disease-related biological mechanisms …

Prostate-specific membrane antigen is a type II membrane glycoprotein that is expressed in
benign and neoplastic prostatic tissue and has been recently shown to be also expressed in …

Early detection of prostate cancer (PCa) and advances in hormonal and chemotherapy
treatments have provided great clinical benefits to patients with early stages of the disease …

The aim of this study was to determine the role of prostate-specific membrane antigen
(PSMA) as a prognostic marker in endometrial adenocarcinoma (EAC) and to explore …